RadNet (RDNT) M&A announcement summary

Deal rationale and strategic fit

• Acquisition creates the largest provider of radiology clinical AI solutions globally, expanding reach and portfolio across all core imaging modalities, including X-ray, MRI, CT, ultrasound, and mammography.

• Gleamer's strong commercial presence in Europe and broad FDA/CE-cleared portfolio aligns with the goal of global expansion and multimodality coverage.

• Addresses rising imaging volumes and radiologist shortages by advancing automated diagnostics and workflow efficiencies.

• Combines strengths in routine imaging, particularly X-ray, with advanced AI and informatics for comprehensive care.

• Gleamer's rapid ARR growth and 700+ customer contracts demonstrate market validation and scalability.

Financial terms and conditions

• All-cash transaction valued at up to €230 million ($270 million), including a post-closing milestone based on 2026 ARR.

• Gleamer expected to deliver $30 million ARR in 2026, with combined entity guidance of $135–$145 million revenue and $120–$140 million ARR for 2026.

• Valuation reflects Gleamer's high recurring revenue growth, strong margins, and customer retention.

Synergies and expected cost savings

• Over $7 million in revenue synergies anticipated from cross-sell and upsell opportunities, with full realization expected by 2027.

• Identified over $4 million in cost synergies, mainly from overlapping vendors and filling pre-existing vacancies, expected to accelerate Gleamer's break-even timeline to mid-2027.

• Integration expected to drive measurable productivity gains, especially in X-ray, which represents 25% of imaging volume.

• Combined ARR projected to approach or exceed $140 million by end of 2026.

• Leveraging DeepHealth's fixed cost platform to quickly improve unit economics.